.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Moodys
US Department of Justice
Citi
Chinese Patent Office
Chubb
Novartis
Medtronic
Daiichi Sankyo
AstraZeneca

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021872

« Back to Dashboard
NDA 021872 describes KEPPRA, which is a drug marketed by Ucb Inc and is included in four NDAs. It is available from seven suppliers. There are two patents protecting this drug and three Paragraph IV challenges. Additional details are available on the KEPPRA profile page.

The generic ingredient in KEPPRA is levetiracetam. There are thirty-five drug master file entries for this compound. Ninety-six suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

Summary for NDA: 021872

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Anticonvulsants
Formulation / Manufacturing:see details

Pharmacology for NDA: 021872

Suppliers and Packaging for NDA: 021872

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KEPPRA
levetiracetam
INJECTABLE;IV (INFUSION) 021872 NDA UCB, Inc. 50474-002 50474-002-63 10 VIAL, SINGLE-USE in 1 CARTON (50474-002-63) > 5 mL in 1 VIAL, SINGLE-USE
KEPPRA
levetiracetam
INJECTABLE;IV (INFUSION) 021872 NDA Cardinal Health 55154-7211 55154-7211-5 5 VIAL in 1 BAG (55154-7211-5) > 5 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)Strength500MG/5ML (100MG/ML)
Approval Date:Jul 31, 2006TE:APRLD:Yes

Expired Orange Book Patents for NDA: 021872

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc
KEPPRA
levetiracetam
INJECTABLE;IV (INFUSION)021872-001Jul 31, 20064,943,639*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Teva
Healthtrust
Citi
Cerilliant
Farmers Insurance
Cipla
Johnson and Johnson
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot